Synapse - Paul Hamlin

Results (293)

Therapeutic and palliative benefit from single-agent irinotecan in multiply treated and highly refractory cases of lymphoma

Meeting Abstract

Caces, D. D.; Halaas, J.; Hamlin, P.; Noy, A.; Kewalramani, T.; Portlock, C. S.; Zelenetz, A. D.; O'Connor, O. A.; Gerecitano, J. F.
Journal of Clinical Oncology (2009)

Fulltext@MSK | Save

Rituximab, cyclophosphamide, bortezomib and prednisone (R-CBorP): Final results of a phase I trial evaluating two dosing schedules and the safety of overlapping pegfilgrastim in patients with relapsed/refractory indolent and mantle cell lymphomas

Meeting Abstract

Gerecitano, J.; Portlock, C. S.; Hamlin, P. A.; Moskowitz, C. H.; Noy, A.; Straus, D. J.; Schulman, P.; Dumitrescu, O.; Sarasohn, D.; Pappanicholaou, J.; more...
Blood (2009)

Fulltext@MSK | Save

Pralatrexate and gemcitabine in patients with relapsed or refractory lymphoproliferative malignancies: Phase 1 results

Meeting Abstract

Horwitz, S. M.; Vose, J. M.; Advani, R.; Sankhala, K.; Padmanabhan, S.; Hamlin, P. A. Jr; Chen, A.; Zain, J. M.; Fruchtman, S.; O'Connor, O. A.
Blood (2009)

Fulltext@MSK | Save

Bendamustine is highly active in heavily pre-treated relapsed and refractory Hodgkin lymphoma and serves as a bridge to allogeneic stem cell transplant

Meeting Abstract

Moskowitz, A. J.; Hamlin, P. A.; Gerecitano, J.; Horwitz, S. M.; Matasar, M.; Meikle, J.; Noy, A.; Palomba, M. L.; Portlock, C. S.; Straus, D. J.; more...
Blood (2009)

Fulltext@MSK | Save

Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies

Journal Article

O'Connor, O. A.; Horwitz, S.; Hamlin, P.; Portlock, C.; Moskowitz, C. H.; Sarasohn, D.; Neylon, E.; Mastrella, J.; Hamelers, R.; Macgregor-Cortelli, B.; more...
Journal of Clinical Oncology (2009)

Fulltext@MSK | Save

Distress in older patients with cancer

Journal Article

Hurria, A.; Li, D. N.; Hansen, K.; Patil, S.; Gupta, R.; Nelson, C.; Lichtman, S. M.; Tew, W. P.; Hamlin, P.; Zuckerman, E.; more...
Journal of Clinical Oncology (2009)

Fulltext@MSK | Save

Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma

Journal Article

Freedman, A.; Neelapu, S. S.; Nichols, C.; Robertson, M. J.; Djulbegovic, B.; Winter, J. N.; Bender, J. F.; Gold, D. P.; Ghalie, R. G.; Stewart, M. E.; more...
Journal of Clinical Oncology (2009)

Fulltext@MSK | Save

Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: Results of a multicentre phase 2 clinical trial

Journal Article

O'Connor, O. A.; Moskowitz, C.; Portlock, C.; Hamlin, P.; Straus, D.; Dumitrescu, O.; Sarasohn, D.; Gonen, M.; Butos, J.; Neylon, E.; more...
British Journal of Haematology (2009)

Fulltext@MSK | Save

The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL)

Journal Article

Noy, A.; Schoder, H.; Gonen, M.; Weissler, M.; Ertelt, K.; Cohler, C.; Portlock, C.; Hamlin, P.; Yeung, H. W. D.
Annals of Oncology (2009)

Fulltext@MSK | Save

A Population pharmacokinetic and pharmacodynamic evaluation of pralatrexate in patients with relapsed or refractory non-hodgkin's or hodgkin's lymphoma

Journal Article

Mould, D. R.; Sweeney, K.; Duffull, S. B.; Neylon, E.; Hamlin, P.; Horwitz, S.; Sirotnak, F.; Fleisher, M.; Saunders, M. E.; O'Connor, O. A.
Clinical Pharmacology & Therapeutics (2009)

Fulltext@MSK | Save